International Journal of Applied Research
Vol. 2, Issue 12, Part G (2016)
Oral azithromycin as the systemic treatment of choice in the treatment of Meibomian gland disease
Y Srinivas, M Parni Kumar and NR Bharathi K
To asses the efficacy and safety of oral Azithromycin when compared with oral doxycycline patients with Meibomian Gland Dysfunction (MGD) who has failed to respond to prior conservative management.
Methods: 30 Patient with MGD were randomly assigned to receive either oral 3 days Azithromycin (500mg/ day) or 3 month Doxycycline (100mg/day). There were 20 Females and 10 males average age 45 years (range 20 to 55) They also continued eye lid warming/ cleaning and artificial tears. Symptoms and signs are recorded prior to treatment and at 1 week, and 1 and 2momths after treatment. side effects are recorded and overall clinical improvement was categorised as excellent, good, fair and poor based on clinical features.
Results: Based on clinical observation excellent score was recorded in 20 cases (66.6%) Good in 6 cases (20%) Fair in 3 cases (10%) Poor in 1 case (3.3%).
Conclusion: This short term study proved Oral Azithromycin is a good alternative for MGD as first line systemic therapy.
How to cite this article:
Y Srinivas, M Parni Kumar and NR Bharathi K. Oral azithromycin as the systemic treatment of choice in the treatment of Meibomian gland disease. International Journal of Applied Research. 2016; 2(12): 443-444.